Upgrade to SI Premium - Free Trial

Alnylam Pharma (ALNY)

266.11 +1.61 (0.61%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26)

Latest Headlines

H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) September 2, 2026 6:54 AM - StreetInsider Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26' September 1, 2026 9:07 AM - StreetInsider Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) August 31, 2026 9:20 AM - StreetInsider Truist Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) August 31, 2026 9:05 AM - StreetInsider TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) August 31, 2026 9:03 AM - StreetInsider BMO Capital on Alnylam Pharmaceuticals (ALNY): 'Strong ATTR Outlook With Limited Readthrough From Eplontersen' August 31, 2026 8:57 AM - StreetInsider Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) August 31, 2026 7:10 AM - StreetInsider Alnylam presents vutrisiran and zilebesiran data at ESC 2026 August 31, 2026 6:04 AM - StreetInsider Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings August 30, 2026 8:23 AM - BizWire Alnylam stock drops on rival heart trial: Why analysts see core business safe August 28, 2026 8:25 AM - StreetInsider Bernstein SocGen Group Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) August 25, 2026 3:31 AM - StreetInsider Alnylam to present ATTR and hypertension data at ESC 2026 August 24, 2026 8:33 AM - StreetInsider Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026 August 24, 2026 8:33 AM - BizWire BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform August 18, 2026 4:13 PM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $256 at Wells Fargo August 14, 2026 8:51 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $455 at H.C. Wainwright August 5, 2026 6:37 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $315 at Truist Securities August 4, 2026 7:09 AM - StreetInsider Raymond James Upgrades Alnylam Pharmaceuticals (ALNY) to Strong Buy August 3, 2026 7:20 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $450 at Barclays August 3, 2026 6:39 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $375 at JPMorgan July 31, 2026 9:20 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $316 at Wells Fargo July 31, 2026 8:35 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Oppenheimer July 31, 2026 8:11 AM - StreetInsider Alnylam Pharma. (ALNY) PT Lowered; RBC Capital: 'Tough Update But Stock Reaction Looks Overdone' July 31, 2026 8:09 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $318 at Stifel July 31, 2026 8:08 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $300 at Morgan Stanley July 31, 2026 8:00 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) July 31, 2026 6:41 AM - StreetInsider Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 July 30, 2026 8:11 AM - SEC Filing Alnylam Pharma (ALNY) Tops Q2 EPS by 24c ; Offers Guidance July 30, 2026 8:09 AM - StreetInsider Form 8-K ALNYLAM PHARMACEUTICALS, For: Jul 30 July 30, 2026 8:06 AM - SEC Filing Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress July 30, 2026 8:00 AM - BizWire Alnylam Pharmaceuticals (ALNY) PT Lowered to $400 at JPMorgan July 22, 2026 7:21 AM - StreetInsider Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results July 16, 2026 8:00 AM - BizWire Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data July 15, 2026 5:50 AM - StreetInsider Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease July 15, 2026 3:30 AM - BizWire Alnylam Pharmaceuticals (ALNY) Reiterated at Buy by Stifel Post CARDIO-TTRansform Failure July 14, 2026 7:29 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright July 14, 2026 6:54 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at BofA Securities July 14, 2026 6:02 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist Securities July 13, 2026 7:08 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $400 at Morgan Stanley July 10, 2026 8:09 AM - StreetInsider Increasing unusual call volume: ACI LEVI IHI FE KHC BBIO IONS OCUL XME DOMO ALNY July 9, 2026 10:33 AM - StreetInsider Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile' July 9, 2026 6:16 AM - StreetInsider Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) June 30, 2026 6:51 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright June 29, 2026 7:06 AM - StreetInsider Komodo Health expands AI platform deal with Alnylam June 25, 2026 9:00 AM - StreetInsider Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform June 25, 2026 9:00 AM - BizWire Alnylam to Host Tenth “RNAi Roundtable” Webcast Series June 12, 2026 9:00 AM - BizWire GENESIS Pharma expands Alnylam partnership to Nordic markets June 10, 2026 7:47 AM - StreetInsider GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region June 10, 2026 7:47 AM - BizWire Full Article List